scispace - formally typeset
Search or ask a question
Journal Article

12-Month Evaluation of Dexamethasone Intravitreal Implant in Patients With Macular Edema Due to Central Retinal Vein Occlusion

17 Apr 2010-Investigative Ophthalmology & Visual Science (The Association for Research in Vision and Ophthalmology)-Vol. 51, Iss: 13, pp 6397-6397
About: This article is published in Investigative Ophthalmology & Visual Science.The article was published on 2010-04-17 and is currently open access. It has received 3 citations till now. The article focuses on the topics: Dexamethasone Intravitreal Implant & Central retinal vein occlusion.
Citations
More filters
Journal ArticleDOI
TL;DR: Investigation of changes in growth factor levels released from human mesenchymal stem cells in the vitreous cavity as well as changes in grow factor levels in host retinal neurons following intravitreal injection confirm the neuroprotective activity of human meschymalstem cells in diabetic retinopathy.
Abstract: Background Intravitreal injection of human mesenchymal stem cells has been shown to be effective in slowing the progression of diabetic retinopathy in an animal model of chemically induced diabetes mellitus. We studied changes in growth factor levels released from human mesenchymal stem cells in the vitreous cavity as well as changes in growth factor levels in host retinal neurons following intravitreal injection. Methods Twenty-two Lewis rats were treated with an intravitreal human mesenchymal stem cell microinjection. Determination of neurotrophic factors released by human mesenchymal stem cells in the vitreous was carried out using real-time polymerase chain reaction. Results Detectable levels of neurotrophic factors were identified postoperatively in the vitreous of all rats. Conclusion Increased intravitreal and retinal concentrations of neuroprotective growth factors in rats confirm the neuroprotective activity of human mesenchymal stem cells in diabetic retinopathy.

35 citations


Cites background from "12-Month Evaluation of Dexamethason..."

  • ...It will be necessary to increase the number of researchers involved in our study group to reach the clinical phase of experimentation for this pathology in the future.(20,21)...

    [...]

Journal ArticleDOI
01 Mar 2011
TL;DR: In this paper, Dexamethason-Implantate sind bereits fur die Therapie von retinalen Venenverschlussen zugelassen and werden hier erfolgreich eingesetzt.
Abstract: Fur die Therapie der nichtinfektiosen Uveitis werden Immunsuppressiva verwendet, sofern keine ausreichende Reiz- und Rezidivfreiheit mit Steroiden in niedriger Dosierung zu erreichen ist. Hierbei werden zum Erhalt des Visus auch bei Erkrankungen, die auf die Augen beschrankt sind, zum Teil erhebliche Nebenwirkungen in Kauf genommen. Wunschenswert ist also eine Therapie, die hochwirksam ist, auf die Augen beschrankt bleibt und ein geringes Nebenwirkungspotenzial aufweist. Hierzu wurden die Fluocinolon-acetonid- und Dexamethason-Implantate entwickelt. Dexamethason-Implantate sind bereits fur die Therapie von retinalen Venenverschlussen zugelassen und werden hier erfolgreich eingesetzt. Das diabetische Makulaodem ist ein weiteres mogliches Einsatzgebiet fur Dexamethason-Implantate.

2 citations